IMTX (Immatics NV) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


IMTX Immatics NV IMTX
60 GF Score
Price $10.20
GF Value $3.57
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immatics NV Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Immatics NV's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

IMTX vs INVA, PGEN, VIR: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Immatics NV's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immatics NV Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immatics NV's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Immatics NV's Margin of Safety % (DCF Earnings Based) falls into.


IMTX
60GF Score
Immatics NV IMTX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immatics NV (IMTX) Overvalued in 2026?

Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued. The current stock price of $10.20 is trading 185.7% above its estimated GF Value™ of $3.57. GuruFocus considers Immatics NV to be Significantly Overvalued.

Key valuation signals for IMTX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $3.57 vs. price of $10.20 (185.7% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immatics NV Business Description

Other Exchanges 4A3:Germany
Address Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score

Get the complete analysis for IMTX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price
$3.57
GF Value